From Medscape Medical News
May 24, 2011 (Chicago, Illinois) — The direct-acting protease inhibitor telaprevir, given in combination with pegylated interferon plus peginterferon/ribavirin (PR), increased the chance of sustained viral response (SVR) across all interleukin (IL) 28B genotypes of hepatitis C virus (HCV), results of a substudy of the ADVANCE trial have shown.
The findings were reported here at Digestive Disease Week 2011 by Ira Jacobson, MD, chief of the division of gastroenterology and hepatology at New York–Presbyterian Hospital/Weill Cornell Medical Center, and Vincent Astor Distinguished Professor of Medicine at Weill Cornell Medical College in New York City. Dr. Jacobson is also principal investigator for the ADVANCE study.
"Single-nucleotide polymorphisms near the IL28B gene have been strongly associated with the likelihood of SVR in genotype 1 HCV patients treated with PR. During our evaluation of an exploratory diagnostic test that characterizes genetic polymorphisms near the IL28B gene, we investigated the impact of the IL28B genotype on SVR rates in the telaprevir-based regimens," Dr. Jacobson said.
The 3 variations of the IL28B genotype have been associated with a person's response to hepatitis C treatment with PR, Dr. Jacobson noted. In this study, substantial improvements were observed in SVR, or viral cure, across all IL28B genotypes — CC, CT, and TT — for patients treated with telaprevir-based combination therapy, he reported.
In ADVANCE, patients were randomized to receive telaprevir (for 8 weeks or 12 weeks) in combination with PR, followed by PR alone, for a total of either 24 weeks or 48 weeks of treatment. In the response-guided regimen, eligibility for the shorter treatment duration was based on having undetectable HCV at weeks 4 and 12.
The IL28B allele distribution in a sample of 454 patients for whom genotyping was available was consistent with previous reports for treatment-naïve patients: 49% had the CT genotype, 33% had the CC genotype, and 18% had the TT genotype.
The SVR rates in these 454 white patients were 78% for the 12-week telaprevir-based regimen, 65% for the 8-week telaprevir-based regimen, and 38% for the control group treated only with PR.
Patients with the CC allele were the most likely to achieve an SVR, which reached 90% with the 12-week regimen and 84% with the 8-week regimen. In the CC allele population receiving only PR, 68% achieved an SVR. In the other 2 allele subsets receiving 12 weeks of telaprevir, SVR was achieved by 71% of CT patients and 73% of TT patients; in those receiving PR only, SVR was achieved by 25% of CT patients and 23% of TT patients.
"You see that the largest increment in SVR occurred in patients with the T allele," Dr. Jacobson pointed out. Rates exceeded 70%, compared with 25% or less with PR only.
With the 8-week regimen, SVR rates were 57% and 59%, respectively, compared with 25% and 23%, respectively, for the PR regimen in these genotype subsets.
Telaprevir-based regimens also improved rapid viral responses (RVRs) and extended (e)RVR rates across all IL28B genotypes, meaning they had undetectable HCV RNA at weeks 4 and 12. The eRVR rate in the 12-week group was higher than in the placebo group for CC patients (78% vs 15%), for CT patients (57% vs 2%), and for TT patients (45% vs 0%).
"Most eRVR patients achieved an SVR in all groups," he added, including 95% of the CC group, 92% of the CT group, and 80% of the TT group receiving 12 weeks of telaprevir plus PR. "Patients with an eRVR were highly likely to achieve SVR as well."
Nonattainment of eRVR was associated with lower SVR rates across all IL28B genotypes, with the largest decrement in CT/TT patients, the study found.
Andrew Muir, MD, clinical director of hepatology at Duke University Medical Center, Durham, North Carolina, told Medscape Medical News that these findings confirm that all patients benefit from the addition of telaprevir, regardless of their IL28B genotype.
When it became clear that the CC genotype is associated with higher response rates, patients who learned they had the CT or TT genotype tended to have concerns, Dr. Muir said. "These findings change that discussion a lot," he noted. "Those patients now see that they can benefit from treatment as well."
The other value of the study is the finding that a patient is more likely to benefit from a shorter course of treatment if he or she [has genotype] CC," he added. "This may be relevant to some patients — that is, it may make a difference in their enthusiasm for treatment. It's important to have this information in your discussions with patients."
Telaprevir was just approved by the US Food and Drug Administration for the treatment of HCV.
Dr. Jacobson reports receiving grant and research support, consulting fees, and other financial benefit from Vertex Pharmaceuticals. Dr. Muir reports receiving research support and other financial benefit from Vertex Pharmaceuticals. Digestive Disease Week (DDW) 2011: Abstract 904. Presented May 10, 2011.
Authors and Disclosures
Journalist
Caroline Helwick
Related;
Hepatitis C.Telaprevir Ups Response Rates Across IL28B Genotypes /
No comments:
Post a Comment